Generex Biotechnology announced that their subsidiary, Olaregen Therapeutix, Inc., received the prestigious "Seal of Approval" from the American Podiatric Medical Association for their Cellular Tissue Product, Excellagen Wound Conforming Matrix. Founded in 1912, the APMA is the leading resource for foot and ankle health information. Currently, the organization represents a vast majority of the estimated 18,000 podiatrists in the U.S. The APMA Seal of Approval/Acceptance Program evaluates the use of therapeutic agents and their adjunct and regulated medical devices. The seal is granted to a product after the Podiatric Seals Committee, a standing committee of the American Podiatric Medical Association, evaluates and determines whether the product allows normal foot function and promotes quality foot health. Additionally, evidence of usefulness and safety must be established, either by an appropriately recognized laboratory or clinical investigation, or by the products meeting certain physical standards. A detailed review is conducted by each committee member on every product. The committee then sends its recommendation to the APMA Board of Trustees, which has the authorization to either accept or reject the recommendation.